Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 24;10(21):4896.
doi: 10.3390/jcm10214896.

Pharmacological Treatments against COVID-19 in Pregnant Women

Ana Arco-Torres  1 , Jonathan Cortés-Martín  1 , María Isabel Tovar-Gálvez  2 , María Montiel-Troya  2 , Blanca Riquelme-Gallego  2 , Raquel Rodríguez-Blanque  3
Affiliations
Review

Pharmacological Treatments against COVID-19 in Pregnant Women

Ana Arco-Torres et al. J Clin Med. .

Abstract

The recent respiratory virus known as SARS-CoV-2 has caused millions of deaths worldwide, causing great uncertainty due to the lack of a specific treatment, which has been mitigated by the use of various drugs traditionally used against other types of pathologies. Pregnancy presents special physiological conditions that expose the pregnant woman and the foetus to greater risk. Pregnant women are often excluded from trials due to possible risk of toxicity or side effects, resulting in a lack of knowledge about the use of drugs and treatments during pregnancy. The main objective of this review was to compile existing knowledge about currently available drug treatments for COVID-19 in pregnant women. The review report met the criteria of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) review protocol and was registered with the registration number CRD42021251036. The electronic databases searched were Scopus, PubMed, CINAHL and SciELO. Finally, 22 articles were included, resulting in an analysis of drugs with an acceptable safety profile in the treatment of pregnant women with COVID-19.

Keywords: COVID-19; SARS-CoV-2; foetus; pharmacological treatment; pregnant woman; virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Peyronnet V., Sibiude J., Huissoud C., Lescure F.X., Lucet J.C., Mandelbrot L., Nisan I., Belaish-Allart J., Vayssiere C., Yazpandanah Y., et al. Infection with SARS-CoV-2 in preg-nancy. Update of Information and proposed care. CNGOF. 2020;48:858–870. - PMC - PubMed
    1. Cavalcante M.B., Cavalcante C.T.D.M.B., Braga A.C.S., Andrade D.A., Montenegro M.A., Santos P.A.N., Motoyama P.V.P., Rocha M.G., Dib L.A., Júnior E.A. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe Frauenheilkd. 2021;81:46–60. - PMC - PubMed
    1. Lambelet V., Vouga M., Pomar L., Favre G., Gerbier E., Panchaud A., Baud D. SARS-CoV-2 in the context of past coronaviruses epidemics: Consideration for prenatal care. Prenat Diagn. 2020;40:1641–1654. doi: 10.1002/pd.5759. - DOI - PMC - PubMed
    1. D’Souza R., Ashraf R., Rowe H., Zipursky J., Clarfield L., Maxwell C., Arzola C., Lapinsky S., Paquette K., Murhy S., et al. Pregnancy and COVID-19: Pharmacologic consider-ations. Ultrasound Obstet. Gynecol. 2021;57:195–203. doi: 10.1002/uog.23116. - DOI - PMC - PubMed
    1. Afshar Y., Silverman N.S., Han C.S., Platt L.D. Clinical guidance and perinatal care in the era of coronavirus disease 2019 (COVID-19) J. Peérinat. Med. 2020;48:925–930. doi: 10.1515/jpm-2020-0400. - DOI - PubMed

LinkOut - more resources